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Autogenous Access
(n  213)
Frosthetic Access
(n  120)
HR (95% CI) p-value HR (95% CI) p-value
Demographics
Increasing age
(years) 1.01 (0.98–1.03) 0.634 1.00 (0.97–1.03) 0.853
African American
Pace 0.56 (0.29–1.09) 0.090 1.48 (0.60–3.67) 0.398
Smoking status
Current Ref Ref
Former 1.00 (0.55–1.83) 0.999 1.38 (0.61–3.04) 0.455
Never 1.02 (0.49–2.14) 0.949 1.18 (0.50–2.79) 0.714
Comorbidities
Diabetes 1.21 (0.74–1.98) 0.444 2.12 (1.01–4.44) 0.047
Hypertension 0.88 (0.55–1.40) 0.584 1.45 (0.69–3.05) 0.326
Previous access in same
arm 0.78 (0.48–1.25) 0.309 0.83 (0.43–1.63) 0.594
Angiotensin receptor
blocker 0.35 (0.15–0.79) 0.012 0.40 (0.17–0.94) 0.035
Beta blocker 0.49 (0.27–0.90) 0.021 1.27 (0.68–2.36) 0.457
Antiplatelet medication 0.75 (0.41–1.37) 0.348 1.02 (0.56–1.86) 0.953
ACE inhibitor 0.80 (0.50–1.27) 0.340 0.51 (0.24–1.06) 0.072
Anti-angina agent 1.05 (0.57–1.95) 0.878 0.65 (0.18–2.30) 0.503
Anticoagulant 0.49 (0.16–1.49) 0.209 N/A1
Calcium channel
blocker 0.77 (0.46–1.31) 0.338 0.63 (0.33–1.23) 0.178
Diuretic 0.74 (0.45–1.23) 0.247 1.48 (0.62–3.43) 0.380
”Statin” (HMG Co-A
reductase
inhibitor) 1.32 (0.77–2.25) 0.312 0.59 (0.27–1.25) 0.166
Anti-hypertensive,
other 1.00 (0.57–1.75) 0.998 1.09 (0.40–2.95) 0.871
Lipid-lowering agent,
other 1.88 (0.58–6.09) 0.294 N/A1
Adjusted Relative Hazard of Access Failure
1Excluded from model due to small sample size using medication (antico-
agulant, n 3; lipid-lowering agent, other, n  1)
Author Disclosures: R. Amdur: Nothing to disclose;
R. A. Macsata: Nothing to disclose; R. S. Maybury:
Nothing to disclose; A. N. Sidawy: Nothing to disclose.
PS174.
Migration, Fracture, and Rupture as Complications of
Endovascular Grafts in the Treatment of Arteriovenous
Fistula
Dennis Wright1, Jill Zink1, Mirnal Chaudry2, Robert Net-
zley1, Victor Erzurum1. 1Akron General Medical Center,
Akron, OH; 2Northeastern Ohio Universities College of
Medicine, Rootstown, OH
Objectives:Endovascular stent grafts are utilized in the
rescue of failing AV access. Reports claim the superiorty of
stent grafts and recommended these as a first line treat-
ment. We have observed a rise in the number of complica-
tions related to stent grafts in our patients.
Methods: We reviewed all patients who had endovas-
cular stent grafts placed for treatment of failing dialysis
access over the last 36 months. A series of 27 consecutively
placed stent grafts was reviewed for stent migration, frac-
ture, hemorrhage and rupture at the site of the stent grafts.
Hospital charts were reviewed to assess for indications,
hemodynamic stability, transfusion requirement, and
outcome.
Results: Of 27 stent grafts placed, 9 were for pseudo-
aneurysm (PS), 15 for stenosis (ST), and 3 for a combina- pion (PS/ST). Six patients (22%) presented with complica-
ions (Table 1) related to migration, fracture, or rupture.
our of the six patients were in the pseudoaneurysm treat-
ent group. In all cases migration or fracture of the stent
raft lead to pseudoaneurysm formation. Four patient’s
equired ligation of the fistula to treat the complication and
wo dialysis access sites were salvaged.
Conclusions: Stent grafing of AV fistulas is seen in
ncreasing numbers of patients. Significant life threatening
omplication can arise when fracture and migration of the
tent grafts occur. Herald bleed with a previously placed
tent graft may be a harbinger of future rupture. Rupture
ppears less likely when stent grafts are used to treat steno-
is; surgical revision in the case of pseudoaneurysm should
e considered for access preservation.
able I.
Presentation and outcomes of stent graft complications # of pts
resented with significant bleeding episode 5
equired emergent/urgent operation 5
erald Bleed (At least 72 hrs prior to presentation) 4
ignificant hemodynamic instability (SBP 90) 3
equired blood transfusion ( 1 unit PRBC) 2
ardiopulmonary Arrest 1
ortality 0
uthor Disclosures: M. Chaudry: Nothing to disclose;
. Erzurum: Nothing to disclose; R. Netzley: Nothing to
isclose;D. Wright: Nothing to disclose; J. Zink: Nothing
o disclose.
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hirty Day Outcomes following Brachiocephalic and
rachiobasilic Arteriovenous Fistula Formation: Na-
ional Benchmarks for Standard of Care
rateek K. Gupta1, Bala Natarajan1, Yeruva M. Reddy1,
imani Gupta1, Marcus Balters1, Jason M. Johanning2,
homas G. Lynch2, R. Armour Forse1, G. Matthew
ongo2, Jason N. MacTaggart2, Iraklis I. Pipinos2.
Creighton University, Omaha, NE; 2University of Ne-
raska Medical Center, Omaha, NE
Objectives: Dialysis access is one of the most fre-
uently performed vascular procedures, however, there is a
aucity of risk-adjusted, population-based data for postop-
rative outcomes following these procedures resulting in a
ack of national benchmarks for quality of care. The objec-
ive of this study was to report 30-day outcomes following
rachiocephalic and brachiobasilic arteriovenous fistula
AVF) formation.
Methods: Patients were identified from the American
ollege of Surgeons’ 2007-08 National Surgical Quality
mprovement Program (NSQIP) - a multicenter (more
han 180 hospitals), prospective database.
Results: In 2,037 patients, median age was 63 years
ith 53.7% being males and 52.1% Caucasians. Median
ody mass index was 28.3 kg/m2. Eighty nine percent
atients had hypertension, 47.0%were diabetics, and 78.7%
